Vascular Specialist International

The Korean Society for Vascular Surgery (대한혈관외과학회)
권호 표지
DOI QR코드

DOI QR Code

Comparison of Outcomes of Hybrid and Surgical Correction for De Novo Arteriovenous Graft Occlusion

  • Ko, Dai Sik (Division of Vascular Surgery, Department of Surgery, Gachon University Gil Medical Center) ;
  • Choi, Sang Tae (Division of Vascular Surgery, Department of Surgery, Gachon University Gil Medical Center) ;
  • Lee, Won Suk (Division of Vascular Surgery, Department of Surgery, Gachon University Gil Medical Center) ;
  • Chun, Yong Soon (Division of Vascular Surgery, Department of Surgery, Gachon University Gil Medical Center) ;
  • Park, Yeon Ho (Division of Vascular Surgery, Department of Surgery, Gachon University Gil Medical Center) ;
  • Kang, Jin Mo (Division of Vascular Surgery, Department of Surgery, Gachon University Gil Medical Center)
  • Received : 2018.07.15
  • Accepted : 2018.09.13
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Purpose: This study aimed to compare surgical revisions and balloon angioplasty after surgical thrombectomy on thrombosed dialysis access as a first event. Materials and Methods: Records of patients undergoing creation of arteriovenous grafts (AVGs) at the Gachon University Gil Medical Center between March 2008 and February 2016 were reviewed. Among them, patients who underwent treatment on first-time thrombotic occlusion after AVG creation were identified. Outcomes were primary, primary-assisted, and secondary patency. The patency was generated using the Kaplan-Meier method, and patency rates were compared by log-rank test. Results: A total of 59 de novo interventions (n=26, hybrid interventions; n=33, surgical revisions) for occlusive AVGs were identified. The estimated 1-year primary patency rates were 47% and 30% in the surgery and hybrid groups, respectively. The estimated primary patency rates were not different between the two groups (log-rank test, P=0.73). The Kaplan-Meier estimates of 6 and 12 months for primary-assisted patency rates were 68% and 57% in the surgery group and 56% and 56% in the hybrid group. The Kaplan-Meier estimates of 12 and 24 months secondary patency rates were 90% and 71% in the surgery group and 79% and 62% in the hybrid group. There were no differences in the estimated primary-assisted and secondary patency rates between the two groups. Conclusion: Our results showed no significant difference between the two groups in terms of primary patency (P=0.73), primary-assisted patency (P=0.85), and secondary patency (P=0.78). However, percutaneous transluminal angioplasty can give more therapeutic options for both surgeons and patients.

Keywords

References

  1. Jin DC. Current status of dialysis therapy for ESRD patients in Korea. J Korean Med Assoc 2013;56:562-568. https://doi.org/10.5124/jkma.2013.56.7.562
  2. Vascular Access 2006 Work Group. Clinical practice guidelines for vascular access. Am J Kidney Dis 2006;48 Suppl 1:S248-273. https://doi.org/10.1053/j.ajkd.2006.04.040
  3. Allon M, Lok CE. Dialysis f istula or graft: the role for randomized clinical trials. Clin J Am Soc Nephrol 2010;5:2348-2354. https://doi.org/10.2215/CJN.06050710
  4. Chan MR, Sanchez RJ, Young HN, Yevzlin AS. Vascular access outcomes in the elderly hemodialysis population: a USRDS study. Semin Dial 2007;20:606-610. https://doi.org/10.1111/j.1525-139X.2007.00370.x
  5. Drew DA, Lok CE, Cohen JT, Wagner M, Tangri N, Weiner DE. Vascular access choice in incident hemodialysis patients: a decision analysis. J Am Soc Nephrol 2015;26:183-191. https://doi.org/10.1681/ASN.2013111236
  6. Gomes A, Schmidt R, Wish J. Reenvisioning fistula first in a patientcentered culture. Clin J Am Soc Nephrol 2013;8:1791-1797. https://doi.org/10.2215/CJN.03140313
  7. Moist LM, Lok CE, Vachharajani TJ, Xi W, AlJaishi A, Polkinghorne KR, et al. Optimal hemodialysis vascular access in the elderly patient. Semin Dial 2012;25:640-648. https://doi.org/10.1111/sdi.12037
  8. Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, et al. Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med 2009;360:2191-2201. https://doi.org/10.1056/NEJMoa0805840
  9. Lok CE, Moist L, Hemmelgarn BR, Tonelli M, Vazquez MA, Dorval M, et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA 2012;307:1809-1816. https://doi.org/10.1001/jama.2012.3473
  10. Wellington JL. Salvage of thrombosed polytetrafluoroethylene dialysis fistulas by interposition grafting. Can J Surg 1983;26:463-465.
  11. Schwartz CI, McBrayer CV, Sloan JH, Meneses P, Ennis WJ. Thrombosed dialysis grafts: comparison of treatment with transluminal angioplasty and surgical revision. Radiology 1995;194:337-341. https://doi.org/10.1148/radiology.194.2.7824708
  12. McCutcheon B, Weatherford D, Maxwell G, Hamann MS, Stiles A. A preliminary investigation of balloon angioplasty versus surgical treatment of thrombosed dialysis access grafts. Am Surg 2003;69:663-667; discussion 668.
  13. Ko PJ, Liu YH, Hsieh HC, Chu JJ, Lin PJ. Initial experience during balloon angioplasty assisted surgical thrombectomy for thrombosed hemodialysis grafts. Chang Gung Med J 2003;26:178-183.
  14. Marston WA, Criado E, Jaques PF, Mauro MA, Burnham SJ, Keagy BA. Prospective randomized comparison of surgical versus endovascular management of thrombosed dialysis access grafts. J Vasc Surg 1997;26:373-380; discussion 381. https://doi.org/10.1016/S0741-5214(97)70030-2
  15. Quencer KB, Oklu R. Hemodialysis access thrombosis. Cardiovasc Diagn Ther 2017;7(Suppl 3):S299-308. https://doi.org/10.21037/cdt.2017.09.08
  16. Lazzaro CR, Trerotola SO, Shah H, Namyslowski J, Moresco K, Patel N. Modified use of the arrow-trerotola percutaneous thrombolytic device for the treatment of thrombosed hemodialysis access grafts. J Vasc Interv Radiol 1999;10:1025-1031. https://doi.org/10.1016/S1051-0443(99)70187-9
  17. Fan SS, Chen CW, Lu KC, Mao HC, Chen MP, Chou CL. A comparison of efficacy of endovascular versus surgical repair for the treatment of arteriovenous fistula stenosis in Taiwan. J Vasc Access 2017;18:200-206. https://doi.org/10.5301/jva.5000669